| __timestamp | Agios Pharmaceuticals, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 40373000 |
| Thursday, January 1, 2015 | 35992000 | 46974000 |
| Friday, January 1, 2016 | 50714000 | 47298000 |
| Sunday, January 1, 2017 | 71124000 | 50918000 |
| Monday, January 1, 2018 | 114145000 | 58044000 |
| Tuesday, January 1, 2019 | 132034000 | 63109000 |
| Wednesday, January 1, 2020 | 149070000 | 65157000 |
| Friday, January 1, 2021 | 121445000 | 68920000 |
| Saturday, January 1, 2022 | 121673000 | 66592000 |
| Sunday, January 1, 2023 | 119903000 | 80393000 |
| Monday, January 1, 2024 | 156784000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This chart compares the SG&A expenses of Agios Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023.
Agios Pharmaceuticals has seen a significant increase in SG&A expenses over the years, peaking in 2020 with a 680% rise from 2014. This growth reflects the company's aggressive expansion and investment in administrative capabilities.
In contrast, Amphastar Pharmaceuticals has maintained a more stable SG&A expense trajectory, with a modest 99% increase over the same period. This stability suggests a more conservative approach to administrative spending.
Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies. As the pharmaceutical industry continues to evolve, monitoring such financial metrics will be key to predicting future success.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.